| Literature DB >> 35702482 |
Hideki Yui1, Kaori Muto2, Yoshimi Yashiro3, Saori Watanabe2, Yukitaka Kiya2, Ayako Kamisato2, Yusuke Inoue2, Zentaro Yamagata1.
Abstract
This paper presents a comparison of the 2021 guidelines for stem cell research and clinical translation outlined by the International Society for Stem Cell Research (ISSCR) with the current regulations in Japan regarding the performance of such research. This paper provides a convenient English-language summary of the Japanese regulations, and illustrates the difference between the ISSCR guidelines and Japanese regulations regarding the conditions of implementation of study activities using human embryos or stem cells, for researchers outside Japan. The regulations governing the performance of research activities using human embryos or stem cells in Japan are relatively complex and comprise a range of laws and guidelines; the specific rules applied depend on the characteristics of each study. Therefore, even similar research activities may differ in terms of not only the guidelines or laws implemented, but also the procedures required. Such situations may confuse researchers.Entities:
Keywords: ESCs, embryonic stem cells; Ethical guidelines; Human embryos; Human stem cells; ISSCR, International Society for Stem Cell Research; International society for stem cell research; Japan; iPSCs, induced pluripotent stem cells
Year: 2022 PMID: 35702482 PMCID: PMC9167854 DOI: 10.1016/j.reth.2022.05.002
Source DB: PubMed Journal: Regen Ther ISSN: 2352-3204 Impact factor: 3.419
The laws and guidelines pertaining to medical research involving human participants that came in effect in Japan as of November 2021.
| The law or guidelines | Year of establishment (the latest revision) |
| (1) Act on Securing the Quality, Efficacy, and Safety of Products, Including Pharmaceuticals and Medical Devices | 1960 (2019) |
| (2) Act on the Regulation of Human Cloning Techniques (Note: The detailed regulations for some of the research activities referred to in this paper are provided in the Guidelines for the Handling of Specified Embryos, which was established under this law in 2001 and last revised in 2021.) | 2000 (2014) |
| (3) Act on the Safety of Regenerative Medicine | 2013 (2018) |
| (4) The Clinical Trials Act | 2017 (2019) |
| (5) Ethical Guidelines for Medical and Biological Research Involving Human Subjects | 2021 (2022) |
| (6) Guidelines for Gene Therapy Clinical Trial | 2015 (2022) |
| (7) Guidelines on the Derivation of Human ES Cells | 2014 (2022) |
| (8) Guidelines on the Utilization of Human ES Cells | 2019 (2022) |
| (9) Guidelines for the Distributing Institute of Human ES Cells | 2019 (2022) |
| (Note. The first guidelines for ESCs were established in 2001 and reorganized several times after that.) | |
| (10) Ethical Guidelines for Assisted Reproductive Technology Research that Involves the Generation of Human Embryos | 2010 (2022) |
| (11) Guidelines on the Research on Producing Germ Cells from Human iPS Cells or Human Tissue Stem Cells | 2010 (2022) |
| (12) Ethical Guidelines for Research that Involves the Use of Technology to Modify Genetic Information in Human Embryos | 2019 (2022) |
Research allocated under category 1A in the ISSCR guidelines and the corresponding regulations in Japan.
| ISSCR Guidelines – Research activities that are exempt from review by a specialized oversight process | The Japanese Regulations |
|---|---|
| a. Research with human pluripotent stem cell lines that is confined to cell culture and involves routine research practices, such as differentiation into tissue-specific cell types. | In cases in which ESCs are not used, such research should be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| b. Research that entails the reprogramming of human somatic cells to pluripotency (for example, the generation of induced pluripotent stem cells). | Such research should be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| c. Research that entails the use of human fetal tissue and cells. | Such research can be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| d. Research on stem cell culture systems that model specific stages of development or specific anatomic structures rather than the continuous development of an intact embryo or fetus. | In cases in which ESCs are not used, such research should be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| e. The transplantation of human stem cells, their derivatives, or other human cells into postnatal animal hosts. |
Research allocated to category 1B in the ISSCR guidelines and the corresponding regulations in Japan.
| ISSCR Guidelines – Research activities that are reportable, but not typically reviewed by a specialized oversight process | The Japanese Regulations |
|---|---|
| a. Research that entails the | In cases in which ESCs are not used, such research should be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| b. Chimeric embryo research in which human pluripotent stem cells are transferred into non- human, mammalian embryos and cultured | Such research should be conducted in accordance with the Act on the Regulation of Human Cloning Techniques. |
| c. Research on | In cases of gametogenesis from iPSCs, such research should be conducted in accordance with the Guidelines on the Research on Producing Germ Cells from Human iPS Cells or Human Tissue Stem Cells. |
Research that is allocated to category 2 of the ISSCR guidelines and the corresponding regulations in the Japanese system.
| ISSCR Guidelines - Research activities that should be reviewed by a specialized oversight process | The Japanese Regulations |
|---|---|
| a. Procurement and use of IVF human embryos for research | The generation of ESCs, the replacement of mitochondria in embryos, and the genetic alteration in embryos, should be conducted in accordance with the corresponding set of guidelines (Guidelines on the Derivation of Human ES Cells, Guidelines for the Handling of Specified Embryos, and Ethical Guidelines for Research that Involves the Use of Technology to Modify Genetic Information in Human Embryos, respectively). For uses other than those listed above, such research can be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| b. Procurement of human gametes to create research embryos | Such research should be conducted in accordance with the Ethical Guidelines for Assisted Reproductive Technology Research that Involves the Generation of Human Embryos. |
| c. Research that generates human gametes from any progenitor cell type | Such research is prohibited by the Guidelines on the Research on Producing Germ Cells from Human iPS Cells or Human Tissue Stem Cells, as well as the Guidelines on the Utilization of Human ES Cells. |
| d. Research involving the genetic alteration of human embryos or gametes used to make embryos | The genetic alteration of surplus embryos should be conducted in accordance with the Ethical Guidelines for Research that Involves the Use of Technology to Modify Genetic Information in Human Embryos. |
| e. Derivation of new cell lines from human embryos (not confined to pluripotent cell lines). | Regarding ESCs, research should be conducted in accordance with the Guidelines on the Derivation of Human ES Cells. |
| f. Research involving the | The cultivation of human embryos up to 14 days from fertilization is allowed, provided the procedure is in accordance with the following guidelines: |
| g. Generation of stem cell-based embryo models that represent the integrated development of the entire embryo including its extraembryonic membranes. | In cases in which ESCs are not used, such research can be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. |
| h. Research aimed at generating human totipotent cells that have the potential to sustain embryonic development | To generate totipotent cells, it is necessary to develop embryos. Therefore, if such research is determined to be within the scope of the research objectives stipulated in the Ethical Guidelines for Assisted Reproductive Technology Research that Involves the Generation of Human Embryos, it can be conducted in accordance with these ethical guidelines using new embryos. |
| i. Chimera research in which human pluripotent stem cells or their derivatives with broad potential are introduced into: a) a non-human embryo or fetus | If the research corresponds to condition a) and does not involve the use of ESCs, it can be conducted in accordance with the Ethical Guidelines for Medical and Biological Research Involving Human Subjects. If such research does involve the use of ESCs, it can be conducted in accordance with the Guidelines on the Utilization of Human ES Cells. |
| j. Transferring human embryos to a human uterus following mitochondrial replacement. | Such research is prohibited by the Act on the Regulation of Human Cloning Techniques. |